Erectile dysfunction (ED) is a major concern in heart failure (HF) due its high prevalence as well as its negative impact on the quality of life, this condition being usually unrecognized and thus untreated. A number of possible causes might contribute to the above mentioned tight association, i.e., shared risk factors, comorbidities and several physiologic HF abnormalities such as impaired exercise tolerance, psychogenic factors and neurohumoral, metabolic and vascular changes. Medications have been blamed for playing also a pivotal role in the ED occurrence and, particularly, the β-blockers. Remarkably, the underlying mechanisms have not been fully identified. All the available scientific literature dealing with this topic derives from studies not addressing this issue in HF, but in other settings, (e.g., arterial hypertension) and are also characterized by important methodological flaws. Thus, given the solid evidences arguing in favor of β-blockers in HF in terms of morbidity, mortality and quality of life, β-blockers at the maximal tolerated dosage in this patients’ category should be recommended, regardless of ED. However, the ED-related issues should not be neglected, and adequate psychological counseling and management should be provided, pursuing the correction of risk factors, the choice of more suitable medications and, in selected cases, adopting specific drugs or devices. The purpose of this narrative review is to highlight the close relationship between ED and HF and, specifically, to focus on a possible β-blockers’ role in determining or, at least, worsening this condition.

β-Blockers and Erectile Dysfunction in Heart Failure. Between Myth and Reality / Corradetti, Sara; Gallo, Giovanna; Correale, Michele; Piepoli, Massimo; Badagliacca, Roberto; Nodari, Savina; Agostoni, Piergiuseppe; Magri', Damiano. - In: REVIEWS IN CARDIOVASCULAR MEDICINE. - ISSN 1530-6550. - 23:5(2022), pp. 1-8. [10.31083/j.rcm2305173]

β-Blockers and Erectile Dysfunction in Heart Failure. Between Myth and Reality

Sara Corradetti;Giovanna Gallo;Roberto Badagliacca;Damiano Magrì
2022

Abstract

Erectile dysfunction (ED) is a major concern in heart failure (HF) due its high prevalence as well as its negative impact on the quality of life, this condition being usually unrecognized and thus untreated. A number of possible causes might contribute to the above mentioned tight association, i.e., shared risk factors, comorbidities and several physiologic HF abnormalities such as impaired exercise tolerance, psychogenic factors and neurohumoral, metabolic and vascular changes. Medications have been blamed for playing also a pivotal role in the ED occurrence and, particularly, the β-blockers. Remarkably, the underlying mechanisms have not been fully identified. All the available scientific literature dealing with this topic derives from studies not addressing this issue in HF, but in other settings, (e.g., arterial hypertension) and are also characterized by important methodological flaws. Thus, given the solid evidences arguing in favor of β-blockers in HF in terms of morbidity, mortality and quality of life, β-blockers at the maximal tolerated dosage in this patients’ category should be recommended, regardless of ED. However, the ED-related issues should not be neglected, and adequate psychological counseling and management should be provided, pursuing the correction of risk factors, the choice of more suitable medications and, in selected cases, adopting specific drugs or devices. The purpose of this narrative review is to highlight the close relationship between ED and HF and, specifically, to focus on a possible β-blockers’ role in determining or, at least, worsening this condition.
2022
heart failure,; beta-blocker; erectile dysfunction
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
β-Blockers and Erectile Dysfunction in Heart Failure. Between Myth and Reality / Corradetti, Sara; Gallo, Giovanna; Correale, Michele; Piepoli, Massimo; Badagliacca, Roberto; Nodari, Savina; Agostoni, Piergiuseppe; Magri', Damiano. - In: REVIEWS IN CARDIOVASCULAR MEDICINE. - ISSN 1530-6550. - 23:5(2022), pp. 1-8. [10.31083/j.rcm2305173]
File allegati a questo prodotto
File Dimensione Formato  
Corradetti_beta-Blockers-and-Erectile-Dysfunction_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 573.89 kB
Formato Adobe PDF
573.89 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1649766
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact